Boticarium III

  1. Medrano Albéniz, Juan
Journal:
Revista de la Asociación Española de Neuropsiquiatría

ISSN: 0211-5735

Year of publication: 2012

Volume: 32

Issue: 115

Pages: 619-631

Type: Article

DOI: 10.4321/S0211-57352012000300013 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista de la Asociación Española de Neuropsiquiatría

Bibliographic References

  • (1) Food and Drug Administration. Clozaril (clozapine) Tablets. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -November 2008 and October 2011. Accesible en: http://www. fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ ucm121329.htm
  • (2) Chennattucherry JJ, Currie A, Piracha I. Tardive dyskinesia: psychiatrists’ knowledge and practice. The Psychiatrist 2011, 35:164-7. Accesible en: http://pb.rcpsych.org/content/35/5/164.full. pdf+html
  • (3) American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-72.
  • (4) Rodríguez-Artalejo F, Baca E, Esmatjes E, Merino-Torres JF, Monereo S, Moreno B, et al. Valoración y control del riesgo metabólico y cardiovascular en los pacientes con esquizofrenia. Med Clin. 2006;127:542-8.
  • (5) Bainbridge E, Gallagher A, McDonald G, McDonald C, Ahmed M. General practitioners’ attitudes on who should manage metabolic dysregulations associated with antipsychotics. The Psychiatrist 2011, 35: 213-5. Accesible en: http://pb.rcpsych.org/ content/35/6/213.full.pdf+html
  • (6) Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of secondvs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-87. Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/17015810
  • (7) Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209-23. Accesible en: http://www.nejm.org/doi/ full/10.1056/NEJMoa061240
  • (8) Bernardo M, Coma A, Ibañez C, Zara C, Bari JM, Serrano-Blanco A. Antipsychotic polypharmacy in a regional health service: a population-based study. BMC Psychiatry 2012, 12:42 doi:10.1186/1471- 244X-12-42. Accesible en: http://www. biomedcentral.com/content/pdf/1471- 244X-12-42.pdf
  • (9) Huys D, Hardenacke K, Poppe P, Bartsch C, Baskin B, Kuhn J. Update on the role of antipsychotics in the treatment of Tourette syndrome. Neuropsychiatr Dis Treat 2012; 8:95-104. Accesible en: http://www. dovepress.com/articles.php?article_id=9453
  • (10) Nuevos datos de seguridad sobre los antipsicóticos Olanzapina y Risperidona en el tratamiento de pacientes ancianos con Psicosis o Trastornos de Conducta asociados a Demencia. Accesible en: http://www. aemps.es/actividad/alertas/usoHumano/seguridad/olanzapina.htm
  • (11) NOTA INFORMATIVA (Ref: 2008/19) de 28 de noviembre de 2008: Anti- psicóticos clásicos y aumento de mortalidad en pacientes ancianos con demencia. Accesible en: http://www.aemps.es/actividad/alertas/usoHumano/seguridad/NI_2008-19_antipsicoticos.htm
  • (12) Huybrechts KF, Schneeweiss S, Gerhard T, Olfson M, Avorn J, Levin R, et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc 2012; 60: 420-9. Abstract accesible en: http://www.ncbi.nlm.nih.gov/pubmed/22329464
  • (13) Sinclair L. Antipsychotics for Elderly Vary in Mortality Risk. Psychiatric News 2012; 47(9): 22-3. Accesible en: http:// psychnews.psychiatryonline.org/newsArticle.aspx?articleid=1130402
  • (14) Huybrechts KF, Schneeweiss S, Gerhard T, Olfson M, Avorn J, Levin R, et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc 2012; 60: 420-9. Abstract accesible en: http://www.ncbi.nlm.nih.gov/pubmed/22329464
  • (15) Alzheimer’s Society. Optimi- sing treatment and care for people with beha- vioural and psychological symptoms of dementia: A best practice guide. Accesible en: http://alzheimers.org.uk/site/scripts/download_info.php?downloadID=609
  • (16) Turner EH, Knoepflmacher D, Shapley L (2012) Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database. PLoS Med 9(3): e1001189. doi:10.1371/journal.pmed.1001189. Accesible en: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal. pmed.1001189
  • (17) Agencia Española de Medicamentos y Productos Sanitarios. Escitalopram: Prolongación del intervalo QT del electrocardiograma. 2 de diciembre de 2011. Accesible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/ seguridad/2011/docs/NI-MUH_23-2011.pdf
  • (18) Zyban (bupropion hydrochloride) Prescribing Information January 2012. Accesible en: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2012/020711s036lbl. pdf
  • (19) Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding asso- ciated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183: 1835-43. Accesible en: http://www.cmaj.ca/content/183/16/1835. full.pdf+html
  • (20) Taylor C. What is the antide- pressant of choice in coronary heart disea- se? London: London Medicines Information Service. Accesible en: http://www.nelm.nhs. uk/en/NeLM-Area/Evidence/Medicines-Q-A/What-is-the-antidepressant-of-choice-inischaemic-heart-disease/
  • (21) Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits From Antidepressants: Synthesis of 6-Week Patient-Level Outcomes From Double-blind Placebo-Controlled Randomized Trials of Fluoxetine and Venlafaxine. Arch Gen Psychiatry 2012; 69: 572-9. Accesible en: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archgenpsychiatry.2011.2044
  • (22) Kirsch I, Deacon BJ, HuedoMedina TB, Scoboria A, Moore TJ, et al. (2008) Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration. PLoS Med 5(2): e45. doi:10.1371/journal. pmed.0050045. Accesible en: http://www. plosmedicine.org/article/info:doi/10.1371/ journal.pmed.0050045
  • (23) Moran M. New Data Rebut Claims About Antidepressants. Psychiatric News 2012; 47 (8): 12a-12a. Accesible en: http://psychnews.psychiatryonline.org/ newsArticle.aspx?articleid=1104014
  • (24) Rothschild AJ. Do Antidepressants Cause Suicide? Psychiatric News 2012; 47 (1): 17b-17b. Accesible en: http://psychnews.psychiatryonline.org/newsArticle. aspx?articleid=181262
  • (25) Guaiana G, Andretta M, Griez E, Biancosino B, Grassi L. Sales of antidepressants, suicides and hospital admissions for depression in Veneto Region, Italy, from 2000 to 2005: an ecological study. Annals of General Psychiatry 2011, 10:24. Accesible en: http://www.annals-general-psychiatry. com/content/10/1/24.
  • (26) Pompili M, Goldblatt MJ. Psychopharmacological Treatment to Reduce Suicide Risk. A Brief Review of Available Medications. Psychiatric Times, 2 de abril de 2012. Accesible en: http://www. psychiatrictimes.com/display/article/10168 /2053799?GUID=D6A56A7B-1628-49E1- BCA8-E107E4DB979E&rememberme=1& ts=08062012#
  • (27) AEMPS. Antiepilépticos y riesgo de alteraciones óseas. Informe mensual medicamentos de uso humano. Octubre 2011. Accesible en: http://www.aemps.gob. es/informa/informeMensual/2011/octubre/ informe-medicamentos.htm
  • (28) García C. Abbott pagará en EE UU una multa de 1.600 millones de dólares por fraude. El País, 8 de mayo de 2012. Accesible en: http://sociedad. elpais.com/sociedad/2012/05/08/actualidad/1336429824_632471.html
  • (29) Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiatry 2012; 169: 134-40. Accesible en: http://ajp.psychiatryonline.org/Article.aspx?articleid=483663
  • (30) Food and Drug Administra- tion. Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants: Drug Safety Communication Use During Pregnancy and Potential Risk of Persistent Pulmonary Hypertension of the Newborn (12/14/2011). Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm283696.htm
  • (31) El Marroun H, Jaddoe VWV, Hudziak JJ, Roza SJ, Steegers EAP, Hofman A, et al. Maternal Use of Selective Serotonin Reuptake Inhibitors, Fetal Growth, and Risk of Adverse Birth Outcomes. Arch Gen Psychiatry. 2012;():1-9. doi:10.1001/ archgenpsychiatry.2011.2333. Accesible en: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archgenpsychiatry.2011.2333
  • (32) Agencia Española de Medicamentos y Productos Sanitarios. Noviembre 2011. Medicamentos de uso humano. Accesible en: http://www.aemps.gob.es/informa/ informeMensual/2011/noviembre/informemedicamentos.htm
  • (33) Scottish Intercollegiate Guideline Network. SIGN guideline: Management of perinatal mood disorders. 22/03/2012. Accesible en: http://www.nelm.nhs.uk/en/ NeLM-Area/Evidence/Guidelines/SIGNguideline-Management-of-perinatal-mooddisorders/
  • (34) MHRA. Drug safety update: Atomoxetine (Strattera): increases in blood pressure and heart rate—new contraindications, warnings, and advice for monitoring. January 2012. Accesible en: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON140666
  • (35) Agencia Española de Medicamentos y Productos Sanitarios. Atomoxetina (Strattera®) y aumento de la presión arterial y frecuencia cardíaca: nuevas recomendaciones. 5 de diciembre de 2011. Accesible en: http://www.aepap.org/sites/default/files/nimuh_25-2011.pdf
  • (36) Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, et al. Methylphenidate and risk of serious cardiovascular events in adults.Am J Psychiatry 2012; 169: 178-85. Accesible en: http://ajp.psychiatryonline.org/article. aspx?articleid=483658
  • (37) Moran M. Stimulants & Cardiovascular Safety: Risk-Benefit Issues Get Clearer. Psychiatric News 2012; 47 (7): 16b-16b. Accesible en: http://psychnews.psychiatryonline.org/newsArticle. aspx?articleid=1096612
  • (38) Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al ADHD medications and risk of serious cardiovascular events in young and middleaged adults. JAMA 2011; 306: 2673-83. Accesible en: http://jama.jamanetwork.com/ article.aspx?doi=10.1001/jama.2011.1830
  • (39) Brooks M. New Evidence Addresses ADHD Meds and Adult CVD Risk. Medscape Psychiatry & Mental Health. Accesible en: http://www.medscape.com/view article/755220?sssdmh=dm1.741709&src= nl_newsalert
  • (40) Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365: 1896-904. Accesible en: http://www.nejm.org/doi/pdf/10.1056/ NEJMoa1110212
  • (41) Moran M. More Research Needed on SSRIs for Treating Autism Disorders. Psychiatric News 2012; 47 (11): 11a-11a. Accesible en: http://psychnews.psychiatryonline.org/newsArticle.aspx?articleid=1170362
  • (42) Carrasco M, Volkmar FR, Bloch MH. Pharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias. Pediatrics 2012; DOI: 10.1542/peds.2011-3285. Accesible en: http://pediatrics.aappublications. org/content/early/2012/04/17/peds.2011- 3285
  • (43) Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, Chandra M, Reed G, Gurwitz JH. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011; 128: 1135-41. Abstract accessible en: http://pediatrics.aappublications.org/content/128/6/1135
  • (44) Sinclair L. Inconsistent Data Link Antipsychotic Use, Diabetes. Psychiatric News 2012; 47 (2): 22a-22a. Accesible en: http://psychnews.psychiatryonline.org/ newsArticle.aspx?articleid=334889
  • (45) Drury SC, Gleason MM. A Delicate Brain: Ethical and Practical Considerations for the Use of Medications in Very Young Children. Psychiatric Times, 28 de febrero de 2012. Accesible en: http:// www.psychiatrictimes.com/display/article/10168/2039638
  • (46) Food and Drug Administration. Chantix (varenicline) Tablets 0.5 mg and 1 mg. Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2012. Accesible en: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ucm290958.htm
  • (47) Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344: e2856. doi: 10.1136/bmj. e2856. Accesible en: http://www.bmj.com/ highwire/filestream/582907/field_highwire_article_pdf/0.pdf
  • (48) Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S (2011) Suicidal Behavior and Depression in Smoking Cessation Treatments. PLoS ONE 6(11): e27016. doi:10.1371/journal.pone.0027016. Accesible en: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0027016
  • (49) Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008; 165: 1033-9. Abstract en: http://www.ncbi.nlm. nih.gov/pubmed/18593778
  • (50) Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165: 1040-7. Abstract en: http://www.ncbi. nlm.nih.gov/pubmed/18381905
  • (51) Hong LE, Thaker GK, McMa- hon RP, Summerfelt A, Rachbeisel J, Fuller RL, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 2011; 68: 1195-206. Accesible en: http://archpsyc.jamanetwork.com/article.aspx?volume=68&is sue=12&page=1195
  • (52) Snyder BD, Polasek TM, Doogue MD. Drug interactions: principles and practice. Australian Prescriber 2012; 35 (3). Accesible en: http://www.australianprescriber.com/magazine/35/3/85/8
  • (53) Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200: 97-106. Abstract en: http://bjp.rcpsych.org/content/200/2/97.abstract
  • (54) Moran M. Psychiatric Drugs’ Efficacy on Par With Those for Other Disorders. Psychiatric News 2012; 47 (9): 1b-28. Accesible en: http://psychnews.psychiatryonline.org/newsArticle. aspx?articleid=1130384
  • (55) Seemüller F, Möller HJ, Dittmann S, Musil R. Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication? BMC Med 2012; 10:17. Accesible en: http:// www.biomedcentral.com/1741-7015/10/17
  • (56) Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, et al. (2012). Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials. PLoS Med 9(4): e1001204. doi:10.1371/journal.pmed.1001204. Accesible en: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal. pmed.1001204
Data source: Dialnet